# 2026-20281: Medicare Launches GLOBE Model to Tame Drug Price Hikes

2026-20281, Global Benchmark for Efficient Drug Pricing (GLOBE) Model, is a Federal Register rule from Health and Human Services Department, Centers for Medicare & Medicaid Services published 2026-10-02, effective 2026-11-30; deemed significant under Executive Order 12866; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2026-20281
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20281
- Title: Global Benchmark for Efficient Drug Pricing (GLOBE) Model
- Type: Rule
- Agencies: Health and Human Services Department; Centers for Medicare & Medicaid Services
- Citation: 91 FR 62936
- Published: 2026-10-02
- Effective: 2026-11-30
- Comments close: not stated
- Significant: yes (OIRA_API)
- Touches household money: yes
- Regulation identifier numbers: 0938-AV66
- Last updated: 2026-11-17

## In one line

Medicare Launches GLOBE Model to Tame Drug Price Hikes

## Summary

Starting November 30, 2026, Medicare will use the new GLOBE Model to help lower the cost of certain drugs for people on Original Medicare. This model changes how drug price increases are calculated, aiming to save money for both patients and the Medicare program without cutting care quality. If you’re on Medicare Part B, expect smarter drug pricing that helps keep your healthcare affordable.

## Abstract

This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs for Original Medicare (OM) beneficiaries and the Medicare program while preserving quality of care. The term OM has the same meaning as Medicare fee-for-service and the traditional Medicare program.

## Effects PRIA read

- Selected Medicare beneficiaries pay less coinsurance: benefit, medium. About 25 percent of Original Medicare (OM) Part B beneficiaries in randomly selected ZIP Code Tabulation Areas (ZCTAs) will be placed in the GLOBE Model cohort and may pay reduced coinsurance for certain Part B drugs. The model begins collecting data January 1, 2027, performance years run April 1,…
- Medicare program expects multi-year cost savings: benefit, medium. CMS estimates the GLOBE Model will reduce Medicare Part B net spending by $440 million over the 7-year payment period (April 1, 2027 through March 31, 2034), including $298 million in Original Medicare Part B benefit savings, $288 million in Medicare Advantage payment savings, and a $147 million pr…
- GLOBE applies only to specific high‑spend Part B drugs: benefit, medium. The model will apply to a subset of Part B rebatable single-source drugs and sole-source biological products within specified USP categories (Antigout Agents, Antineoplastics, Blood Products and Modifiers, Central Nervous System Agents, Immunological Agents, Metabolic Bone Disease Agents, and Ophth…
- Manufacturers must pay GLOBE rebates; data collection starts January 2027: cost, medium. Manufacturers of Part B rebatable drugs that are GLOBE Model drugs are mandatory model participants and will be required to pay incremental GLOBE Model rebates when the benchmarked amount exceeds the statutory inflation-adjusted payment amount. CMS will begin collecting voluntary manufacturer-submi…
- Providers must reduce beneficiary coinsurance and will receive adjusted payments: benefit, low. Providers and suppliers who furnish GLOBE Model drugs to GLOBE Model beneficiaries will continue to bill and be paid under Medicare Part B, but when reduced beneficiary coinsurance applies the provider must lower the coinsurance charged and Medicare’s program payment to the provider will be adjuste…

## Related documents

- [2026-22792](https://policyrisk.com/federal-register/2026-22792): Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program, 2026-11-09
- [2026-22750](https://policyrisk.com/federal-register/2026-22750): Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the E…, 2026-11-09
- [2026-22743](https://policyrisk.com/federal-register/2026-22743): Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage…, 2026-11-09
- [2026-22739](https://policyrisk.com/federal-register/2026-22739): Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; i…, 2026-11-06
- [2026-22381](https://policyrisk.com/federal-register/2026-22381): Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage, 2026-11-03
- [2026-22194](https://policyrisk.com/federal-register/2026-22194): Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury (AKI) Dialysis Paym…, 2026-10-30

## Sources
- [2026-20281 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/02/2026-20281/global-benchmark-for-efficient-drug-pricing-globe-model)
- [2026-20281 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-02/pdf/2026-20281.pdf)

## Related
- [Previous: 2026-20276, State of Indiana: Discontinuance of Certain Commission Regulatory Authority Wit…](https://policyrisk.com/federal-register/2026-20276)
- [Next: 2026-20324, Special Local Regulation; Allegheny River Mile Marker 20.5-21, Creighton, PA](https://policyrisk.com/federal-register/2026-20324)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20281 (as of 2026-11-17).
